MRI-based extensor carpi ulnaris tendon cross-sectional area as a quantitative biomarker for extensor carpi ulnaris tenosynovitis
Frontiers in Digital Health · 29.07.2026 · 8
DOI: 10.3389/fdgth.2026.1881901 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Frontiers in Digital Health, online erschienen am 29.07.2026. Verfasst von Jung Min Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesia and Pain Medicine, CHA Ilsan Medical Center, CHA University, Goyang City, Republic of Korea. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Extensor carpi ulnaris tenosynovitis (ECUT) is a common cause of ulnar-sided wrist pain and is often associated with tendon hypertrophy. Although extensor carpi ulnaris tendon thickness (ECUTT) has been used to assess tendon enlargement, a one-dimensional measurement may not fully reflect morphological changes of the tendon. We therefore investigated the diagnostic value of extensor carpi ulnaris tendon cross-sectional area (ECUTCSA) measured on magnetic resonance imaging (MRI) as a quantitative imaging biomarker for ECUT.
Methods
In this retrospective case-control study, MRI examinations from 26 patients with clinically diagnosed ECUT and 26 control subjects were analyzed. Axial T1-weighted wrist MR images were reviewed by two musculoskeletal radiologists who were blinded to clinical information. ECUTCSA and ECUTT were measured at the level demonstrating maximal tendon hypertrophy. Group comparisons were performed using unpaired t-tests, and diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Interobserver agreement was assessed using intraclass correlation coefficients (ICCs).
Results
The mean ECUTCSA was significantly greater in the ECUT group than in the control group (10.86 ± 2.32 mm 2 vs. 7.25 ± 2.52 mm 2 , p < 0.001). The optimal ECUTCSA cutoff value was 8.80 mm 2 , yielding a sensitivity of 84.6%, specificity of 84.6%, and an area under the ROC curve (AUC) of 0.89. The optimal ECUTT cutoff value was 1.98 mm, with an AUC of 0.88. Interobserver agreement was excellent for ECUTCSA (ICC = 0.92) and ECUTT (ICC = 0.88).
Conclusion
ECUTCSA is a reproducible quantitative MRI parameter associated with ECU tenosynovitis and demonstrated good diagnostic performance in this study. These findings support the potential role of ECUTCSA as an imaging biomarker for quantitative assessment of tendon hypertrophy. Further multicenter studies with larger cohorts are warranted to validate its clinical utility.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesia and Pain Medicine, CHA Ilsan Medical Center, CHA University, Goyang City, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, National Police Hospital, Seoul, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Catholic Kwandong University, College of Medicine, International ST. Mary`s Hospital, Incheon, Republic of Korea.
Zitieren
APA
Lee, J. M., Lee, J., Kang, K. N., Heo, B. Y., Shin, D. H., Hong, K. Y., Moon, S., & Kim, Y. U. (2026). MRI-based extensor carpi ulnaris tendon cross-sectional area as a quantitative biomarker for extensor carpi ulnaris tenosynovitis. Frontiers in Digital Health, 8. https://doi.org/10.3389/fdgth.2026.1881901
Vancouver
Lee JM, Lee J, Kang KN, Heo BY, Shin DH, Hong KY, et al. MRI-based extensor carpi ulnaris tendon cross-sectional area as a quantitative biomarker for extensor carpi ulnaris tenosynovitis. Frontiers in Digital Health. 2026;8. doi:10.3389/fdgth.2026.1881901
BibTeX
@article{Lee2026,
author = {Lee, Jung Min and Lee, Joohyun and Kang, Keum Nae and Heo, Burn Young and Shin, Da Huin and Hong, Kwan Young and Moon, Sunyoung and Kim, Young Uk},
title = {MRI-based extensor carpi ulnaris tendon cross-sectional area as a quantitative biomarker for extensor carpi ulnaris tenosynovitis},
journal = {Frontiers in Digital Health},
year = {2026},
volume = {8},
doi = {10.3389/fdgth.2026.1881901}
}
EUVIMED